Trials / Unknown
UnknownNCT03544021
CART-19 FOR Relapsed/Refractory Acute Lymphoblastic Leukemia （ALL）
CD19-Targeted CAR-T in Treating Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia （ALL）
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- Sponsor
- The Affiliated Hospital of the Chinese Academy of Military Medical Sciences · Academic / Other
- Sex
- All
- Age
- 14 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and efficiency of CD19-Targeted CAR-T in Treating Patients with relapsed/refractory acute leukemia.
Detailed description
The relapsed/refractory ALL patients will receive FC (F,Fludarabine，C，Cyclophosphamide) chemotherapy followed by infusion of allogenic or autologous CD19-Targeted CAR-T cells.No graft-versus-host disease (GVHD) prevention will be conducted before or after infusion. Dose-limiting toxicity,incidence of adverse events and disease response will be detected post-infusion.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CART-19 cells | CD19-Targeted CAR-T cells are infused to patient received FC chemotherapy |
Timeline
- Start date
- 2018-03-01
- Primary completion
- 2019-03-01
- Completion
- 2020-03-01
- First posted
- 2018-06-01
- Last updated
- 2018-06-04
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03544021. Inclusion in this directory is not an endorsement.